低剂量依替巴肽治疗卒中串联闭塞:安全性与颈动脉通畅性
回顾性分析58例接受低剂量依替巴肽(135 mcg/kg 弹丸式注射,1 mcg/kg/min 输注)治疗的串联闭塞卒中患者,症状性颅内出血1例(2%),24-36小时颈动脉再闭塞4例(7%),30-60天颈动脉总通畅率42/49(86%),90天mRS 0-2分42例(72%)。
要点
- 低剂量依替巴肽方案下症状性颅内出血发生率2%,24-36小时颈动脉再闭塞7%。
- 30-60天颈动脉总通畅率为86%(42/49),延迟再闭塞3例。
- 颈动脉再闭塞与临床下降无关,90天mRS 0-2分占72%。
诊断标准与关键数值
- 中位年龄64岁,中位NIHSS评分15分。
- 25例(43%)接受tPA治疗;ASPECTS 8-10分47例(81%),5-7分11例(19%)。
- 38例急性期行血管成形术/支架置入,20例仅行血管成形术。
- 症状性颅内出血1例(2%);TICI 2b或以上56例(96%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Maintaining carotid patency and avoiding symptomatic intracranial hemorrhage are competing concerns in tandem occlusions. This study provides data regarding the safety and efficacy of eptifibatide in stroke from tandem occlusion of the extracranial carotid artery and the intracranial carotid or middle cerebral artery.
MATERIALS AND METHODS: This is a retrospective analysis of 58 consecutive patients who received low-dose eptifibatide (135-mcg/kg bolus, 1-mcg/kg/min infusion) during treatment of tandem occlusions. Brain imaging and carotid sonography were performed at 24-36 hours. mRS was documented at 90 days, and carotid sonography, at 30-60 days.
RESULTS: The median age and NIHSS score were 64 years and 15, respectively. Twenty-five patients (43%) received tPA. ASPECTSs were 8-10 in 47 (81%) and 5-7 in 11 (19%) patients. Thirty-eight patients had angioplasty/stent placement acutely; 20 had angioplasty alone. Symptomatic intracranial hemorrhage occurred in 1 patient (2%). TICI 2b or higher was achieved in 56 patients (96%). Fifty-seven of 58 patients had clinical follow-up at 90 days (1 lost to follow up). The 90-day mRS was 0-2 in 42 patients (72%). There were 4/58 (7%) re-occlusions within 24-36 hours, all originally treated with stent placement. Forty-nine of 53 surviving patients had carotid sonography at 30-60 days, with 3 delayed re-occlusions, 2 with stents and 1 with angioplasty alone. The overall carotid patency at 30-60 days was 42/49 (86%). Carotid re-occlusion was not associated with clinical decline.
CONCLUSIONS: Low-dose eptifibatide seemed to be safe in tandem occlusions (symptomatic intracranial hemorrhage, 2%), although asymptomatic cervical carotid artery re-occlusions still occurred in 14% of patients.
引用
- Jost A, Roels C, Brown M, et al. Low-Dose Eptifibatide for Tandem Occlusion in Stroke: Safety and Carotid Artery Patency. AJNR Am J Neuroradiol. 2021. PMID: 33541892. doi:10.3174/ajnr.A6985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。